SV2017005459A - Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr - Google Patents

Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr

Info

Publication number
SV2017005459A
SV2017005459A SV2017005459A SV2017005459A SV2017005459A SV 2017005459 A SV2017005459 A SV 2017005459A SV 2017005459 A SV2017005459 A SV 2017005459A SV 2017005459 A SV2017005459 A SV 2017005459A SV 2017005459 A SV2017005459 A SV 2017005459A
Authority
SV
El Salvador
Prior art keywords
pan fgfr
treatment
pan
identifying patients
cancer
Prior art date
Application number
SV2017005459A
Other languages
English (en)
Inventor
Peter Ellinghaus
Melanie Heroult
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SV2017005459A publication Critical patent/SV2017005459A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

LA PRESENTE INVENCIÓN SE BASA EN UN INHIBIDOR DE PAN FGFR PARA USAR EN EL TRATAMIENTO DEL CÁNCER EN UN SUJETO, DONDE EL SUJETO ES AQUEL PARA QUIEN SE HA ENCONTRADO QUE LA SUMA DE ARNM DE FGFR1, FGFR2 Y/O FGFR3 EN UNA MUESTRA DE TEJIDO TUMORAL DEL SUJETO ESTÁ SOBRE-EXPRESADA
SV2017005459A 2014-12-11 2017-06-09 Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr SV2017005459A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14197400 2014-12-11

Publications (1)

Publication Number Publication Date
SV2017005459A true SV2017005459A (es) 2018-07-09

Family

ID=52015993

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005459A SV2017005459A (es) 2014-12-11 2017-06-09 Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr

Country Status (18)

Country Link
US (1) US20180333418A1 (es)
EP (1) EP3229800A2 (es)
JP (1) JP2017538708A (es)
KR (1) KR20170090431A (es)
CN (1) CN106999592A (es)
AU (1) AU2015359538A1 (es)
BR (1) BR112017012287A2 (es)
CA (1) CA2970181A1 (es)
CL (1) CL2017001487A1 (es)
EA (1) EA201791236A1 (es)
IL (1) IL252187B (es)
JO (1) JO3730B1 (es)
MX (1) MX2017007656A (es)
PH (1) PH12017501064A1 (es)
SG (1) SG11201704090WA (es)
SV (1) SV2017005459A (es)
TW (1) TW201628655A (es)
WO (1) WO2016091849A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3566705B1 (en) * 2017-01-06 2022-11-23 Lemonex Inc. Composition for preventing or treating metastatic ovarian cancer, endometrial cancer or breast cancer
RU2771311C2 (ru) * 2017-08-15 2022-04-29 Сиэсписи Чжунци Фармасьютикал Текнолоджи (Шишцзяжуан) Ко., Лтд. Ингибитор fgfr и его медицинское применение
WO2019111998A1 (ja) * 2017-12-08 2019-06-13 京ダイアグノスティクス株式会社 癌スフェロイドの製造方法および大腸癌患者の選択方法
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN118354772A (zh) * 2021-11-16 2024-07-16 北京诺诚健华医药科技有限公司 治疗头颈癌的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105584D0 (en) * 2011-04-01 2011-05-18 Imp Innovations Ltd Cancer methods
UY34484A (es) * 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
EP2695950A1 (en) * 2012-08-10 2014-02-12 Blackfield AG Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
EP3237638B1 (en) * 2014-12-24 2020-01-15 F.Hoffmann-La Roche Ag Therapeutic, diagnostic and prognostic methods for cancer of the bladder

Also Published As

Publication number Publication date
CL2017001487A1 (es) 2018-02-23
CN106999592A (zh) 2017-08-01
AU2015359538A1 (en) 2017-06-08
WO2016091849A2 (en) 2016-06-16
IL252187B (en) 2020-07-30
CA2970181A1 (en) 2016-06-16
IL252187A0 (en) 2017-07-31
TW201628655A (zh) 2016-08-16
EP3229800A2 (en) 2017-10-18
EA201791236A1 (ru) 2018-01-31
PH12017501064A1 (en) 2017-12-04
WO2016091849A3 (en) 2016-07-28
MX2017007656A (es) 2017-10-11
SG11201704090WA (en) 2017-06-29
JP2017538708A (ja) 2017-12-28
JO3730B1 (ar) 2021-01-31
BR112017012287A2 (pt) 2018-08-28
KR20170090431A (ko) 2017-08-07
US20180333418A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
CL2017001487A1 (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr.
MX391470B (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
ECSP15026557A (es) Compuestos y sus métodos de empleo
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
CL2015002807A1 (es) Terapia de combinación
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
MX387283B (es) Tratamiento del cancer con tg02.
CL2019002438A1 (es) Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5.
MX2015000008A (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX2016012667A (es) Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
CL2022000522A1 (es) Lurbinectedina en el tratamiento del mesotelioma maligno.
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
MX2017016346A (es) Metodos de tratamiento con taselisib.
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака
MA40636A (fr) Procédés pour détecter le cancer de la prostate
CL2017000578A1 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia